NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213

CompletedPhase 3

Sponsor: Pfizer

Conditions: Rheumatoid Arthritis

Interventions: PF-06410293, adalimumab

Countries: United States, Bosnia and Herzegovina, Bulgaria, Czechia, Lithuania, Poland, Russia, Serbia

The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of RA based on 2010 ACR/EULAR for RA for at least a 4 month duration.
* Moderately to severely active RA based on local standard of care.

Exclusion Criteria:

-Evidence of untreated or inadequately treated latent or active TB.

Locations (72)

Bowling Green, Kentucky, United States
Duncansville, Pennsylvania, United States
Dallas, Texas, United States
Beckley, West Virginia, United States
Banja Luka, Bosnia and Herzegovina
Gradiska, Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina
Pleven, Bulgaria
Plovdiv, Bulgaria
Plovdiv, Bulgaria
Brno, Czechia
Brno, Czechia
Brno, Czechia
Brno, Czechia
Brno, Czechia
Hlučín, Czechia
Hlučín, Czechia
Olomouc, Czechia
Olomouc, Czechia
Olomouc, Czechia
Ostrava, Czechia
Pardubice, Czechia
Pardubice, Czechia
Prague, Czechia
Prague, Czechia
Prague, Czechia
Prague, Czechia
Prague, Czechia
Uherské Hradiště, Czechia
+ 42 more on CT.gov